Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL111512 | 0.89 | EPHX1 (0.39) | EPHX1 | |
| SCHEMBL729887 | 0.85 | CYP2C19 (0.33) | LMNA | |
| SCHEMBL56162 | 0.84 | LMNA (0.38) | EPHX1LMNA | |
| SCHEMBL28897340 | 0.83 | LMNA (0.32) | LMNA | |
| SCHEMBL24178934 | 0.83 | LMNA (0.32) | LMNA | |
| SCHEMBL28540736 | 0.83 | EPHX1 (0.39) | EPHX1 | |
| SCHEMBL200380 | 0.83 | EPHX1 (0.42) | EPHX1 | |
| SCHEMBL9795663 | 0.82 | LMNA (0.36) | EPHX1LMNA | |
| SCHEMBL6064085 | 0.82 | LMNA (0.39) | LMNA | |
| SCHEMBL15327667 | 0.81 | CYP2C19 (0.33) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9795694-B2 | Imaging beta-amyloid peptides aggregation | HONG KONG BAPTIST UNIVERSITY (HK) | 2017-10-24 | — | — | US | disclosed |
| EP-2142558-B1 | HYDROLYZABLE SILANES OF LOW VOC-GENERATING POTENTIAL AND RESINOUS COMPOSITIONS CONTAINING SAME | MOMENTIVE PERFORMANCE MAT INC (US) | 2016-10-05 | — | — | EP | disclosed |
| US-20160243264-A1 | Imaging Beta-Amyloid Peptides Aggregation | HONG KONG BAPTIST UNIVERSITY (HK) | 2016-08-25 | — | — | US | disclosed |
| EP-2137198-B1 | EPOXYSILANES, PROCESSES FOR THEIR MANUFACTURE AND CURABLE COMPOSITIONS CONTAINING SAME | MOMENTIVE PERFORMANCE MAT INC (US) | 2016-05-18 | — | — | EP | disclosed |
| EP-2160424-B1 | CURABLE SILYL-CONTAINING POLYMER COMPOSITION CONTAINING PAINT ADHESION ADDITIVE | MOMENTIVE PERFORMANCE MAT INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8747804-B2 | Modified zinc oxide particles | BASF SE (DE) | 2014-06-10 | — | — | US | disclosed |
| US-8088940-B2 | Having an organofunctional group bonded to a silicon atom through a stable bridging group that is able to react with an organic resin (2,2,4,4,6-pentamethyl-[1,3,2]dioxasilinane); enhanced storage stability, adhesion strength, durability, filler dispersibility, tensile strength, elongation, tear strength | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-7989651-B2 | trimethoxysilylpropyl-carbamic acid oxiranylmethyl ester; reacting glycidol with gamma-isocyanatopropyltriethoxysilane in presence of dibutyltin laurate catalyst | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110130273-A1 | MODIFIED ZINC OXIDE PARTICLES | BASF SE (DE) | 2011-06-02 | — | — | US | disclosed |
| US-20100184887-A1 | HYBRID NANOPARTICLES | BASF SE (DE) | 2010-07-22 | — | — | US | disclosed |
| EP-2142558-A1 | HYDROLYZABLE SILANES OF LOW VOC-GENERATING POTENTIAL AND RESINOUS COMPOSITIONS CONTAINING SAME | Momentive Performance Materials Inc. (US) | 2010-01-13 | — | — | EP | disclosed |
| EP-2137198-A1 | EPOXYSILANES, PROCESSES FOR THEIR MANUFACTURE AND CURABLE COMPOSITIONS CONTAINING SAME | Momentive Performance Materials Inc. (US) | 2009-12-30 | — | — | EP | disclosed |
| US-7569645-B2 | Curable silyl-containing polymer composition containing paint adhesion additive | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2009-08-04 | — | — | US | disclosed |
| WO-2009005642-A1 | CURABLE SILYL-CONTAINING POLYMER COMPOSITION CONTAINING PAINT ADHESION ADDITIVE | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| US-20090005498-A1 | Curable silyl-containing polymer composition containing paint adhesion additive | MOMENTIVE PERFORMANCE MATERIALS INC. | 2009-01-01 | — | — | US | disclosed |
| WO-2008121360-A1 | HYDROLYZABLE SILANES OF LOW VOC-GENERATING POTENTIAL AND RESINOUS COMPOSITIONS CONTAINING SAME | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2008-10-09 | — | — | WO | disclosed |
| US-20080237537-A1 | Hydrolyzable silanes of low VOC-generating potential and resinous compositions containing same | MOMENTIVE PERFORMANCE MATERIALS INC. | 2008-10-02 | — | — | US | disclosed |
| WO-2008112150-A1 | EPOXYSILANES, PROCESSES FOR THEIR MANUFACTURE AND CURABLE COMPOSITIONS CONTAINING SAME | MOMENTIVE PERFORMANCE MATERIALS INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20080221238-A1 | Epoxysilanes, processes for their manufacture and curable compositions containing same | MOMENTIVE PERFORMANCE MATERIALS INC. | 2008-09-11 | — | — | US | disclosed |
| US-7390628-B2 | Microparticle-based diagnostic methods | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2008-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130273-A1 | MODIFIED ZINC OXIDE PARTICLES | SOD1, LPO, SOD3 | EPHX1 3226/4885LMNA 3595/4885 |
| US-20080237537-A1 | Hydrolyzable silanes of low VOC-generating potential and resinous compositions containing same | GSTM1, GSTP1, GSTM2 | EPHX1 148/4885LMNA 3705/4885 |
| US-20100184887-A1 | HYBRID NANOPARTICLES | RAB5IF, TTPA, PRNP | EPHX1 3044/4885LMNA 398/4885 |
| US-20160243264-A1 | Imaging Beta-Amyloid Peptides Aggregation | APP, IAPP, APBA1 | EPHX1 3826/4885LMNA 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.